SCHEMBL1103403

SCHEMBL1103403

Cc1ccc(-c2c3ccccc3c(-c3ccccc3)c3c2cnc2ccccc23)cc1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.47
ALDH1A1 P00352 4/20 0.40
HTT P42858 3/20 0.40
HPGD P15428 3/20 0.40
NPSR1 Q6W5P4 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MAPT P10636 2/20 0.40
RAB9A P51151 2/20 0.39
PDGFRB P09619 1/20 0.39
KDR P35968 1/20 0.39
FLT3 P36888 1/20 0.39
PSMB5 P28074 1/20 0.38
TLR7 Q9NYK1 1/20 0.37
ESR1 P03372 2/20 0.37
ESR2 Q92731 2/20 0.37
TOP2A P11388 1/20 0.36
ADORA2A P29274 1/20 0.36
KDM4E B2RXH2 1/20 0.36
RECQL P46063 1/20 0.36
PDPK1 O15530 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103265 0.96 NPC1 (0.50) NPC1ALDH1A1HTTHPGDNPSR1
SCHEMBL1103524 0.88 NPC1 (0.47) NPC1ALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL1103407 0.88 ALDH1A1 (0.43) NPC1ALDH1A1HTTHPGDNPSR1
SCHEMBL1103449 0.87 ESR1 (0.42) NPC1ALDH1A1HTTHPGDNPSR1
SCHEMBL1103491 0.87 ESR1 (0.42) NPC1ALDH1A1HTTHPGDNPSR1
SCHEMBL1103486 0.87 ESR1 (0.42) NPC1ALDH1A1HTTHPGDNPSR1
SCHEMBL1103479 0.87 ESR1 (0.42) NPC1ALDH1A1HTTHPGDNPSR1
SCHEMBL1103411 0.86 ALDH1A1 (0.52) NPC1ALDH1A1HTTHPGDNPSR1
SCHEMBL1103483 0.86 ESR1 (0.42) NPC1ALDH1A1HTTHPGDNPSR1
SCHEMBL1103478 0.86 ESR1 (0.42) NPC1ALDH1A1HTTHPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 NPC1 1582/4885ALDH1A1 1015/4885HTT 4390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.